联环药业获得法莫替丁注射液药品注册证书

Core Viewpoint - The company has received the drug registration certificate for Famotidine injection from the National Medical Products Administration, which enhances its product line and market competitiveness [1] Summary by Relevant Sections - Product Approval - The company has obtained the drug registration certificate for Famotidine injection, a medication that works by inhibiting gastric acid secretion and belongs to the H2 receptor antagonist class [1] - Impact on Product Line - The approval of Famotidine injection enriches the company's product offerings, contributing to improved market competitiveness [1] - Financial Impact - The acquisition of the drug registration certificate is not expected to have a significant impact on the company's recent operating performance [1]